SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Vindis C.) ;lar1:(ki)"

Sökning: WFRF:(Vindis C.) > Karolinska Institutet

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Tunon, J, et al. (författare)
  • Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
  • 2018
  • Ingår i: European journal of preventive cardiology. - : Oxford University Press (OUP). - 2047-4881 .- 2047-4873. ; 25:9, s. 948-955
  • Tidskriftsartikel (refereegranskat)abstract
    • Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. In fact, low-density lipoprotein (LDL)-lowering drugs have anti-inflammatory effects. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) has shown that interleukin (IL)-1β blockade reduces the incidence of cardiovascular events in patients with previous myocardial infarction and C-reactive protein levels >2 mg/L. These data confirm the connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 inflammasome that leads to IL-1β activation. LDL-lowering drugs are the foundation of cardiovascular prevention. Now, the CANTOS trial demonstrates that combining them with IL-1β blockade further decreases the incidence of cardiovascular events. However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce cardiovascular risk as opposed to only one randomized trial of IL-1β blockade. In addition, IL-1β blockade has only been studied in patients with C-reactive protein >2 mg/L, while the benefit of LDL-lowering is not restricted to these patients. Also, lipid-lowering drugs are not harmful even at very low ranges of LDL, while anti-inflammatory therapies may confer a higher risk of developing fatal infections and sepsis. In the future, more clinical trials are needed to explore whether targeting other inflammatory molecules, both related and unrelated to the IL-1β pathway, reduces the cardiovascular risk. In this regard, the ongoing trials with methotrexate and colchicine may clarify whether the cardiovascular benefit of IL-1β blockade extends to other anti-inflammatory mechanisms. A positive result would represent a major change in the future treatment of atherosclerosis.
  •  
4.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (4)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Liu, X (1)
Chen, L (1)
Alonso, A. (1)
Chen, S. (1)
Chen, X. (1)
Chen, Y. (1)
visa fler...
Donadelli, M. (1)
Gupta, S. (1)
Hu, D. (1)
Jiang, Y. (1)
Jin, S. (1)
Kim, H. (1)
Kono, T. (1)
Li, B. (1)
Li, S. (1)
Li, Y. (1)
Liu, Y. (1)
Meyer, C. (1)
Mohapatra, S. (1)
Nakamura, K. (1)
Nilsson, P. (1)
Shimizu, S. (1)
Takahashi, Y. (1)
Wang, C. (1)
Wang, F. (1)
Wang, H. (1)
Wang, J. (1)
Wang, K. (1)
Wu, M. (1)
Xu, L. (1)
Yamamoto, A. (1)
Yan, Z. (1)
Yang, H. (1)
Yang, Y. (1)
Yu, J. (1)
Zhang, H. (1)
Zhang, L. (1)
Zhang, X. (1)
Zhang, Z. (1)
Zhou, B. (1)
Zhu, H. (1)
Liu, J. (1)
Zhao, Y. (1)
Lange, C. (1)
Li, X. (1)
Zhao, L. (1)
Liu, C. (1)
Liu, H. (1)
Saito, T (1)
Banerjee, S. (1)
visa färre...
Lärosäte
Umeå universitet (1)
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy